Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Workiva Inc — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while Workiva Inc trades at $72.22 (market cap $3.95B). The key difference: Oruka Therapeutics Inc. Common Stock is the larger of the two by market cap, and Oruka Therapeutics Inc. Common Stock is more actively traded (685,276 versus 1,200,755). Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Workiva Inc for 20 Days on average.
| ORKA | WK | |
|---|---|---|
Market Cap | $5.08B | $3.95B |
Volume | 685,276 | 1,200,755 |
Sector | Health | Technology |
52-Week High | $113.08 | $93.31 |
52-Week Low | $26.19 | $44.31 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $4.21B | $3.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WK trades at $72.50, down 0.74% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $86.00. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue grew to $966 million in 2026, turning a net loss in 2025 into a $47 million profit, reflecting improved operational efficiency and strong gross margins above 80%.
The outlook is positive given earnings beats, AI-driven product innovations, and inclusion in positive media coverage, but high valuation multiples like a P/E of 86.48 pose risks if growth slows. Investors should weigh the strong analyst buy consensus against execution risks in a competitive software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
